U.S. judge blocks Colorado’s first-of-its-kind price cap on an Amgen drug

A federal judge has issued a ruling to block a first-of-its-kind price cap on Amgen's blockbuster drug Enbrel in Colorado. The decision halts a move by the Colorado Prescription Drug Affordability Board to establish an upper payment limit for the medication, which was deemed unaffordable by the state panel. This ruling represents a significant legal victory for the pharmaceutical industry as it challenges state-level efforts to control rising prescription drug costs.

A federal judge has ruled in favor of Amgen, blocking the Colorado Prescription Drug Affordability Board (PDAB) from implementing a price cap on the company’s blockbuster drug, Enbrel. The judge determined that the drugmaker was "likely to be significantly harmed" by the payment limit, leading to a pause in what would have been a first-in-the-nation move. This decision is seen as a major win for the pharmaceutical sector, which has been fighting state-led initiatives to regulate drug pricing through affordability boards.

The Colorado PDAB was established four years ago as a legislative response to the escalating costs of prescription medicines. The board is authorized to select specific drugs deemed unaffordable and set upper payment limits on what most residents within the state will pay for those treatments. While several other states have created similar affordability boards with varying rules and criteria, Colorado has been moving more quickly than other states in choosing medicines that are deemed to be unaffordable and proceeding with decisions to create upper payment limits.

The legal intervention highlights the ongoing tension between state governments and pharmaceutical companies over drug affordability and access. Amgen’s successful challenge to the PDAB's authority sets a potential precedent for other states that have established similar boards but have not yet reached the stage of enforcing payment limits. The ruling underscores the judicial hurdles that state-level drug pricing regulations face when challenged by industry stakeholders on the grounds of economic harm.